martes, 7 de mayo de 2019

The prevalence and significance of isolated hepatitis B core antibody (anti-HBc) in endemic population | BMC Research Notes | Full Text

The prevalence and significance of isolated hepatitis B core antibody (anti-HBc) in endemic population | BMC Research Notes | Full Text

BMC Research Notes

The prevalence and significance of isolated hepatitis B core antibody (anti-HBc) in endemic population

  • Email author,
  •  and
BMC Research Notes201912:251
  • Received: 21 February 2019
  • Accepted: 30 April 2019
  • Published: 

Abstract

Objective

There are three major serologic markers for hepatitis B virus (HBV) infection: hepatitis B surface antigen (HBsAg); hepatitis B surface antibody (anti-HBs); and hepatitis B core antibody (anti-HBc). HBV screening programs, however, often test only HBsAg and anti-HBs, missing those individuals who have anti-HBc as the only detectable marker. Isolated anti-HBc can represent chronic infection in which HBsAg is not detectable by serology. We, therefore, investigated the prevalence of isolated anti-HBc in an ethnic community at moderate to high risk for HBV infection.

Results

Of 7157 Korean American adults in New Jersey, 2736 (38.2%) lacked anti-HBs, potentially susceptible to HBV. Of these 2736 subjects, 771 subjects had anti-HBc. The prevalence of isolated anti-HBc increased with age: 0.8% (age 21–30); 2.4% (age 31–40); 6.05% (age 41–50); 11.7% (age 51–60); 18.3% (age 61–70); and 24.5% (age 71–91). Similarly, the percentage of the individuals with isolated anti-HBc in anti-HBs lacking subjects showed a striking age dependence. We conclude that serologic HBV screening should include anti-HBc to accurately assess the prevalence of HBV exposure. Serologic screening with only HBsAg and anti-HBs may overestimate the prevalence of non-immune population. It can also underestimate the prevalence of HBV and increase the risk of HBV reactivation during immunosuppression.

Keywords

  • Hepatitis B virus (HBV)
  • Hepatitis B core antibody (anti-HBc)
  • Antiviral prophylaxis
  • Hepatitis B screening
  • HBV reactivation

No hay comentarios:

Publicar un comentario